Spotlight on Genetics
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision
StartActivity Details
MOC Points
0.50 Contact Hour(s)
Expires: December 19, 2019
Jointly Provided by
Target Audience
This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).
Learning Objectives
- Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
- Interpret the results of genomic testing accurately, including working effectively with genetic counselors
- Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
- Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families
Activity Description
This webinar provides an overview of PARP inhibitor therapy for patients with breast cancer, including use as single-agent therapy, and ongoing studies evaluating PARP inhibitors in combination with chemotherapy and immunotherapy for this patient population.
Statement of Educational Need
MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.
Faculty
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
The following faculty report that they have relevant financial relationships to disclose:
- Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland
The following faculty report that they have relevant financial relationships to disclose:
- Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.
MOC Reviewers
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut
The following faculty report that they have relevant financial relationships to disclose:
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin
The following faculty report that they have no relevant financial relationships to disclose:
- Patrick Thomas Grogan, MD, PhD
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of TFF,
ACCC and ONS. The France Foundation is accredited by the ACCME to provide
continuing medical education for physicians.
The Oncology Nursing Society is accredited with distinction as a provider of
continuing nursing education by the American Nurses Credentialing Center's
(ANCC) Commission on Accreditation.
ONS is approved as a provider of continuing education by the California Board
of Registered Nursing, Provider #2850.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of
0.50 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Maintenance of Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.50 Medical
Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC
point(s) equivalent to the amount of CME credits claimed for the activity. It
is the CME activity provider's responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregate participant data will be shared with commercial supporters of this
activity.
Participants in PARP Inhibitors: Advancing Personalized Medicine for
Patients with Metastatic Breast Cancer – Future Vision can earn a
maximum of 0.50 contact hours of CNE upon the successful completion of this
continuing education activity. No partial credit will be given.
Participants must view sessions in their entirety and submit a completed
evaluation within the specified time frame to receive CNE credit. NOTE: It is
not required to complete all three parts of the series to claim your CNE
certificate for one of the parts.
ILNA Information
The program content has been reviewed by the Oncology Nursing Certification
Corporation (ONCC) and is acceptable for recertification points. CNE sessions
have been classified into the following ILNA categories for all certification
renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)
- Diagnosis and Staging – 0.50 points
- Treatment – 0.50 points
Method of Participation / How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
Statement of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
MOC Points
0.50 Contact Hour(s)
Expires: December 19, 2019
Jointly Provided by
Target Audience
This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).
Learning Objectives
- Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
- Interpret the results of genomic testing accurately, including working effectively with genetic counselors
- Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
- Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families
Activity Description
This webinar provides an overview of PARP inhibitor therapy for patients with breast cancer, including use as single-agent therapy, and ongoing studies evaluating PARP inhibitors in combination with chemotherapy and immunotherapy for this patient population.
Statement of Educational Need
MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.
Faculty
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
The following faculty report that they have relevant financial relationships to disclose:
- Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland
The following faculty report that they have relevant financial relationships to disclose:
- Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.
MOC Reviewers
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut
The following faculty report that they have relevant financial relationships to disclose:
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin
The following faculty report that they have no relevant financial relationships to disclose:
- Patrick Thomas Grogan, MD, PhD
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of TFF,
ACCC and ONS. The France Foundation is accredited by the ACCME to provide
continuing medical education for physicians.
The Oncology Nursing Society is accredited with distinction as a provider of
continuing nursing education by the American Nurses Credentialing Center's
(ANCC) Commission on Accreditation.
ONS is approved as a provider of continuing education by the California Board
of Registered Nursing, Provider #2850.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of
0.50 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Maintenance of Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.50 Medical
Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC
point(s) equivalent to the amount of CME credits claimed for the activity. It
is the CME activity provider's responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregate participant data will be shared with commercial supporters of this
activity.
Participants in PARP Inhibitors: Advancing Personalized Medicine for
Patients with Metastatic Breast Cancer – Future Vision can earn a
maximum of 0.50 contact hours of CNE upon the successful completion of this
continuing education activity. No partial credit will be given.
Participants must view sessions in their entirety and submit a completed
evaluation within the specified time frame to receive CNE credit. NOTE: It is
not required to complete all three parts of the series to claim your CNE
certificate for one of the parts.
ILNA Information
The program content has been reviewed by the Oncology Nursing Certification
Corporation (ONCC) and is acceptable for recertification points. CNE sessions
have been classified into the following ILNA categories for all certification
renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)
- Diagnosis and Staging – 0.50 points
- Treatment – 0.50 points
Method of Participation / How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
Statement of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Genetics Presentations
Are You Ready for Gene Replacement Therapy? Example from Spinal Muscular Atrophy
StartActivity Details
Genetic Counselor CEUs
Expires: June 2, 2020
Accredited By
Target Audience
U.S. geneticists and genetic counselors
International neurologists, pediatricians and geneticists
Learning Objectives
- Explain the genetic aspects of SMA
- Review the recessive nature of SMA
- Discuss SMA carrier status
- Discuss genetic screening recommendations
- Explain status of newborn testing addition to screening panel
- List states that have added newborn SMA testing
- Explore the potential implications of gene replacement therapy for SMA
- Summarize key clinical trial data on available/emerging treatments for SMA
Activity Description
Gene replacement therapy is gaining FDA approval in several therapeutic areas. In this roundtable discussion, three clinicians explain the different types of gene therapy and discuss risks and clinical trial results using spinal muscular atrophy (SMA) as an example.
Statement of Educational Need
Gene therapy is still a mystery to most clinicians. New therapies, such as gene therapy, prompt a reevaluation of the standards of care for patients with spinal muscular atrophy (SMA). Many clinicians have questions regarding SMA genetics.
Agenda
- A Patient’s Story
- Genetics of SMA
- Screening and Genetic Testing
- Treatment Options
- Gene Therapy 101
- Gene Replacement Therapy in SMA
- Panel Discussion of Common Questions
Faculty
Kennedy Family Professor of Pediatrics and Medicine
Columbia University
New York, NY
- No relevant financial relationships to disclose
Assistant Professor
Department of Pediatrics
University of Colorado School of Medicine
Children’s Hospital Colorado
Aurora, CO
- Melissa Gibbons, MS, CGC, serves on advisory boards for Sarepta and AveXis.
Attending Physician, Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Assistant Professor of Pediatrics
Northwestern University
Feinberg School of Medicine
Chicago, IL
- Vamshi Rao, MD, serves on the advisory board for AveXis and is a principal investigator for a clinical trial for NS Pharma.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME/CE committee or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this live activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Genetic Counselor CEUs
The National Society of Genetic Counselors (NSGC) has authorized The France
Foundation to offer up to 0.1 CEUs or 1 Category 1 contact hour for the
activity Are You Ready for Gene Replacement Therapy? Example from SMA. The
American Board of Genetic Counseling (ABGC) will accept CEUs earned at this
program for the purposes of genetic counselor certification and
recertification.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving AMA PRA Category 1 Credit. The first 50 participants requesting NSGC CEUs are free. All others must submit $25 payment. Instructions will be sent with a link for payment within a month of completing the activity.
- Review the activity objectives and CME/CE/CEU information.
- Participate in the CME/CE/CEU activity.
- Complete the CME/CE/CEU evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect his/her professional practice, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting CME or CE credit, your certificate of credit or certificate of participation will be immediately available for download.
- If you are requesting NSGC CEU credit, The France Foundation will submit all documentation of activity completion to NSGC. Your CEU certificate will be issued by the end of the calendar year in which you complete the activity. Please note that your NSGC User ID is required to claim credit. Visit www.nsgc.org to find your user ID.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis, Inc.
Disclosure of Unlabeled Use
TFF requires CME/CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME/CE activity, please contact The
France Foundation at
Activity Details
Genetic Counselor CEUs
Expires: June 2, 2020
Accredited By
Target Audience
U.S. geneticists and genetic counselors
International neurologists, pediatricians and geneticists
Learning Objectives
- Explain the genetic aspects of SMA
- Review the recessive nature of SMA
- Discuss SMA carrier status
- Discuss genetic screening recommendations
- Explain status of newborn testing addition to screening panel
- List states that have added newborn SMA testing
- Explore the potential implications of gene replacement therapy for SMA
- Summarize key clinical trial data on available/emerging treatments for SMA
Activity Description
Gene replacement therapy is gaining FDA approval in several therapeutic areas. In this roundtable discussion, three clinicians explain the different types of gene therapy and discuss risks and clinical trial results using spinal muscular atrophy (SMA) as an example.
Statement of Educational Need
Gene therapy is still a mystery to most clinicians. New therapies, such as gene therapy, prompt a reevaluation of the standards of care for patients with spinal muscular atrophy (SMA). Many clinicians have questions regarding SMA genetics.
Agenda
- A Patient’s Story
- Genetics of SMA
- Screening and Genetic Testing
- Treatment Options
- Gene Therapy 101
- Gene Replacement Therapy in SMA
- Panel Discussion of Common Questions
Faculty
Kennedy Family Professor of Pediatrics and Medicine
Columbia University
New York, NY
- No relevant financial relationships to disclose
Assistant Professor
Department of Pediatrics
University of Colorado School of Medicine
Children’s Hospital Colorado
Aurora, CO
- Melissa Gibbons, MS, CGC, serves on advisory boards for Sarepta and AveXis.
Attending Physician, Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Assistant Professor of Pediatrics
Northwestern University
Feinberg School of Medicine
Chicago, IL
- Vamshi Rao, MD, serves on the advisory board for AveXis and is a principal investigator for a clinical trial for NS Pharma.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME/CE committee or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this live activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Genetic Counselor CEUs
The National Society of Genetic Counselors (NSGC) has authorized The France
Foundation to offer up to 0.1 CEUs or 1 Category 1 contact hour for the
activity Are You Ready for Gene Replacement Therapy? Example from SMA. The
American Board of Genetic Counseling (ABGC) will accept CEUs earned at this
program for the purposes of genetic counselor certification and
recertification.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving AMA PRA Category 1 Credit. The first 50 participants requesting NSGC CEUs are free. All others must submit $25 payment. Instructions will be sent with a link for payment within a month of completing the activity.
- Review the activity objectives and CME/CE/CEU information.
- Participate in the CME/CE/CEU activity.
- Complete the CME/CE/CEU evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect his/her professional practice, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting CME or CE credit, your certificate of credit or certificate of participation will be immediately available for download.
- If you are requesting NSGC CEU credit, The France Foundation will submit all documentation of activity completion to NSGC. Your CEU certificate will be issued by the end of the calendar year in which you complete the activity. Please note that your NSGC User ID is required to claim credit. Visit www.nsgc.org to find your user ID.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis, Inc.
Disclosure of Unlabeled Use
TFF requires CME/CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME/CE activity, please contact The
France Foundation at
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring
StartActivity Details
MOC Points
0.25 Contact Hour(s)
Expires: December 19, 2019
Jointly Provided by
Target Audience
This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).
Learning Objectives
- Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
- Interpret the results of genomic testing accurately, including working effectively with genetic counselors
- Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
- Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families
Activity Description
This case-based webinar includes implications of genetic testing for treatment decisions, and reviews the safety and efficacy of FDA-approved PARP inhibitors for patients with metastatic or advanced breast cancer with germline BRCA mutations.
Statement of Educational Need
MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.
Faculty
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
The following faculty report that they have relevant financial relationships to disclose:
- Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.
Nurse Practitioner
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
The following faculty report that they have no relevant financial relationships to disclose:
- Jennie Petruney, ANP
MOC Reviewers
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut
The following faculty report that they have relevant financial relationships to disclose:
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin
The following faculty report that they have no relevant financial relationships to disclose:
- Patrick Thomas Grogan, MD, PhD
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of TFF,
ACCC and ONS. The France Foundation is accredited by the ACCME to provide
continuing medical education for physicians.
The Oncology Nursing Society is accredited with distinction as a provider of
continuing nursing education by the American Nurses Credentialing Center's
(ANCC) Commission on Accreditation.
ONS is approved as a provider of continuing education by the California Board
of Registered Nursing, Provider #2850.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Maintenance of Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC
point(s) equivalent to the amount of CME credits claimed for the activity. It
is the CME activity provider's responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregate participant data will be shared with commercial supporters of this
activity.
Participants in PARP Inhibitors: Advancing Personalized Medicine for
Patients with Metastatic Breast Cancer – Understanding and Applying PARP
Inhibitor Data to Selection and Monitoring can earn a maximum
of 0.25 contact hours of CNE upon the successful completion of this
continuing education activity. No partial credit will be given.
Participants must view sessions in their entirety and submit a completed
evaluation within the specified time frame to receive CNE credit. NOTE: It is
not required to complete all three parts of the series to claim your CNE
certificate for one of the parts.
ILNA Information
The program content has been reviewed by the Oncology Nursing Certification
Corporation (ONCC) and is acceptable for recertification points. CNE sessions
have been classified into the following ILNA categories for all certification
renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)
- Coordination of Care – 0.25 points
- Diagnosis and Staging – 0.25 points
- Treatment – 0.25 points
Method of Participation / How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
Statement of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
MOC Points
0.25 Contact Hour(s)
Expires: December 19, 2019
Jointly Provided by
Target Audience
This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).
Learning Objectives
- Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
- Interpret the results of genomic testing accurately, including working effectively with genetic counselors
- Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
- Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families
Activity Description
This case-based webinar includes implications of genetic testing for treatment decisions, and reviews the safety and efficacy of FDA-approved PARP inhibitors for patients with metastatic or advanced breast cancer with germline BRCA mutations.
Statement of Educational Need
MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.
Faculty
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
The following faculty report that they have relevant financial relationships to disclose:
- Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.
Nurse Practitioner
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
The following faculty report that they have no relevant financial relationships to disclose:
- Jennie Petruney, ANP
MOC Reviewers
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut
The following faculty report that they have relevant financial relationships to disclose:
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin
The following faculty report that they have no relevant financial relationships to disclose:
- Patrick Thomas Grogan, MD, PhD
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of TFF,
ACCC and ONS. The France Foundation is accredited by the ACCME to provide
continuing medical education for physicians.
The Oncology Nursing Society is accredited with distinction as a provider of
continuing nursing education by the American Nurses Credentialing Center's
(ANCC) Commission on Accreditation.
ONS is approved as a provider of continuing education by the California Board
of Registered Nursing, Provider #2850.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Maintenance of Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC
point(s) equivalent to the amount of CME credits claimed for the activity. It
is the CME activity provider's responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregate participant data will be shared with commercial supporters of this
activity.
Participants in PARP Inhibitors: Advancing Personalized Medicine for
Patients with Metastatic Breast Cancer – Understanding and Applying PARP
Inhibitor Data to Selection and Monitoring can earn a maximum
of 0.25 contact hours of CNE upon the successful completion of this
continuing education activity. No partial credit will be given.
Participants must view sessions in their entirety and submit a completed
evaluation within the specified time frame to receive CNE credit. NOTE: It is
not required to complete all three parts of the series to claim your CNE
certificate for one of the parts.
ILNA Information
The program content has been reviewed by the Oncology Nursing Certification
Corporation (ONCC) and is acceptable for recertification points. CNE sessions
have been classified into the following ILNA categories for all certification
renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)
- Coordination of Care – 0.25 points
- Diagnosis and Staging – 0.25 points
- Treatment – 0.25 points
Method of Participation / How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
Statement of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision
StartActivity Details
MOC Points
0.50 Contact Hour(s)
Expires: December 19, 2019
Jointly Provided by
Target Audience
This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).
Learning Objectives
- Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
- Interpret the results of genomic testing accurately, including working effectively with genetic counselors
- Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
- Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families
Activity Description
This webinar provides an overview of PARP inhibitor therapy for patients with breast cancer, including use as single-agent therapy, and ongoing studies evaluating PARP inhibitors in combination with chemotherapy and immunotherapy for this patient population.
Statement of Educational Need
MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.
Faculty
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
The following faculty report that they have relevant financial relationships to disclose:
- Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland
The following faculty report that they have relevant financial relationships to disclose:
- Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.
MOC Reviewers
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut
The following faculty report that they have relevant financial relationships to disclose:
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin
The following faculty report that they have no relevant financial relationships to disclose:
- Patrick Thomas Grogan, MD, PhD
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of TFF,
ACCC and ONS. The France Foundation is accredited by the ACCME to provide
continuing medical education for physicians.
The Oncology Nursing Society is accredited with distinction as a provider of
continuing nursing education by the American Nurses Credentialing Center's
(ANCC) Commission on Accreditation.
ONS is approved as a provider of continuing education by the California Board
of Registered Nursing, Provider #2850.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of
0.50 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Maintenance of Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.50 Medical
Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC
point(s) equivalent to the amount of CME credits claimed for the activity. It
is the CME activity provider's responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregate participant data will be shared with commercial supporters of this
activity.
Participants in PARP Inhibitors: Advancing Personalized Medicine for
Patients with Metastatic Breast Cancer – Future Vision can earn a
maximum of 0.50 contact hours of CNE upon the successful completion of this
continuing education activity. No partial credit will be given.
Participants must view sessions in their entirety and submit a completed
evaluation within the specified time frame to receive CNE credit. NOTE: It is
not required to complete all three parts of the series to claim your CNE
certificate for one of the parts.
ILNA Information
The program content has been reviewed by the Oncology Nursing Certification
Corporation (ONCC) and is acceptable for recertification points. CNE sessions
have been classified into the following ILNA categories for all certification
renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)
- Diagnosis and Staging – 0.50 points
- Treatment – 0.50 points
Method of Participation / How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
Statement of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
MOC Points
0.50 Contact Hour(s)
Expires: December 19, 2019
Jointly Provided by
Target Audience
This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).
Learning Objectives
- Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
- Interpret the results of genomic testing accurately, including working effectively with genetic counselors
- Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
- Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families
Activity Description
This webinar provides an overview of PARP inhibitor therapy for patients with breast cancer, including use as single-agent therapy, and ongoing studies evaluating PARP inhibitors in combination with chemotherapy and immunotherapy for this patient population.
Statement of Educational Need
MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.
Faculty
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
The following faculty report that they have relevant financial relationships to disclose:
- Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland
The following faculty report that they have relevant financial relationships to disclose:
- Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.
MOC Reviewers
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut
The following faculty report that they have relevant financial relationships to disclose:
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin
The following faculty report that they have no relevant financial relationships to disclose:
- Patrick Thomas Grogan, MD, PhD
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of TFF,
ACCC and ONS. The France Foundation is accredited by the ACCME to provide
continuing medical education for physicians.
The Oncology Nursing Society is accredited with distinction as a provider of
continuing nursing education by the American Nurses Credentialing Center's
(ANCC) Commission on Accreditation.
ONS is approved as a provider of continuing education by the California Board
of Registered Nursing, Provider #2850.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of
0.50 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Maintenance of Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.50 Medical
Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC
point(s) equivalent to the amount of CME credits claimed for the activity. It
is the CME activity provider's responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregate participant data will be shared with commercial supporters of this
activity.
Participants in PARP Inhibitors: Advancing Personalized Medicine for
Patients with Metastatic Breast Cancer – Future Vision can earn a
maximum of 0.50 contact hours of CNE upon the successful completion of this
continuing education activity. No partial credit will be given.
Participants must view sessions in their entirety and submit a completed
evaluation within the specified time frame to receive CNE credit. NOTE: It is
not required to complete all three parts of the series to claim your CNE
certificate for one of the parts.
ILNA Information
The program content has been reviewed by the Oncology Nursing Certification
Corporation (ONCC) and is acceptable for recertification points. CNE sessions
have been classified into the following ILNA categories for all certification
renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)
- Diagnosis and Staging – 0.50 points
- Treatment – 0.50 points
Method of Participation / How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
Statement of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use
StartActivity Details
MOC Points
0.75 Contact Hour(s)
Expires: December 19, 2019
Jointly Provided by
Target Audience
This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).
Learning Objectives
- Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
- Interpret the results of genomic testing accurately, including working effectively with genetic counselors
- Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
- Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families
Activity Description
This case-based webinar reviews criteria for BRCA1/2 testing, the importance of obtaining family history for patients with cancer, interpretation of genetic testing results for patients with metastatic breast cancer and their families, and ways to access genetic services.
Statement of Educational Need
MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.
Faculty
Genetic Counselor
North Memorial Health Cancer Center
Robbinsdale, Minnesota
The following faculty report that they have no relevant financial relationships to disclose:
- Joy Larsen Haidle, MS, CGC
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland
The following faculty report that they have relevant financial relationships to disclose:
- Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.
MOC Reviewers
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut
The following faculty report that they have relevant financial relationships to disclose:
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin
The following faculty report that they have no relevant financial relationships to disclose:
- Patrick Thomas Grogan, MD, PhD
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of TFF,
ACCC and ONS. The France Foundation is accredited by the ACCME to provide
continuing medical education for physicians.
The Oncology Nursing Society is accredited with distinction as a provider of
continuing nursing education by the American Nurses Credentialing Center's
(ANCC) Commission on Accreditation.
ONS is approved as a provider of continuing education by the California Board
of Registered Nursing, Provider #2850.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of
0.75 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Maintenance of Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.75 MOC point(s)
in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC point(s) equivalent
to the amount of CME credits claimed for the activity. It is the CME activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data
will be shared with commercial supporters of this activity.
Participants in PARP Inhibitors: Advancing Personalized Medicine for
Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and
Implications for Targeted Therapy Use can earn a maximum
of 0.75 contact hours of CNE upon the successful completion of this
continuing education activity. No partial credit will be given.
Participants must view sessions in their entirety and submit a completed
evaluation within the specified time frame to receive CNE credit. NOTE: It is
not required to complete all three parts of the series to claim your CNE
certificate for one of the parts.
ILNA Information
The program content has been reviewed by the Oncology Nursing Certification
Corporation (ONCC) and is acceptable for recertification points. CNE sessions
have been classified into the following ILNA categories for all certification
renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON).
- Diagnosis and Staging – 0.75 points
- Treatment – 0.75 points
Method of Participation / How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
Statement of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
MOC Points
0.75 Contact Hour(s)
Expires: December 19, 2019
Jointly Provided by
Target Audience
This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).
Learning Objectives
- Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
- Interpret the results of genomic testing accurately, including working effectively with genetic counselors
- Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
- Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families
Activity Description
This case-based webinar reviews criteria for BRCA1/2 testing, the importance of obtaining family history for patients with cancer, interpretation of genetic testing results for patients with metastatic breast cancer and their families, and ways to access genetic services.
Statement of Educational Need
MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.
Faculty
Genetic Counselor
North Memorial Health Cancer Center
Robbinsdale, Minnesota
The following faculty report that they have no relevant financial relationships to disclose:
- Joy Larsen Haidle, MS, CGC
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland
The following faculty report that they have relevant financial relationships to disclose:
- Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.
MOC Reviewers
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut
The following faculty report that they have relevant financial relationships to disclose:
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin
The following faculty report that they have no relevant financial relationships to disclose:
- Patrick Thomas Grogan, MD, PhD
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
This activity has been planned and implemented in accordance with the
accreditation requirements and policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint providership of TFF,
ACCC and ONS. The France Foundation is accredited by the ACCME to provide
continuing medical education for physicians.
The Oncology Nursing Society is accredited with distinction as a provider of
continuing nursing education by the American Nurses Credentialing Center's
(ANCC) Commission on Accreditation.
ONS is approved as a provider of continuing education by the California Board
of Registered Nursing, Provider #2850.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of
0.75 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Maintenance of Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.75 MOC point(s)
in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC point(s) equivalent
to the amount of CME credits claimed for the activity. It is the CME activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data
will be shared with commercial supporters of this activity.
Participants in PARP Inhibitors: Advancing Personalized Medicine for
Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and
Implications for Targeted Therapy Use can earn a maximum
of 0.75 contact hours of CNE upon the successful completion of this
continuing education activity. No partial credit will be given.
Participants must view sessions in their entirety and submit a completed
evaluation within the specified time frame to receive CNE credit. NOTE: It is
not required to complete all three parts of the series to claim your CNE
certificate for one of the parts.
ILNA Information
The program content has been reviewed by the Oncology Nursing Certification
Corporation (ONCC) and is acceptable for recertification points. CNE sessions
have been classified into the following ILNA categories for all certification
renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON).
- Diagnosis and Staging – 0.75 points
- Treatment – 0.75 points
Method of Participation / How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
Statement of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.